Healthcare in a Changing Climate 2025

95. Vinci, L. (2022). New Report Shows 28% Increase in YoY Funding for Rare Disease Drug Development in 2021. Global Genes, Business Wire. https://www.businesswire.com/news/home/20220112005794/en/New-Report-Shows-28- Increase-in-YoY-Funding-for-Rare-Disease-Drug-Development-in-2021. 96. Pearson, C., Schapiro, L. & Pearson, S.D. (2022). The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability. Institute for Clinical and Economic Review (ICER). https://icer.org/wp-content/ uploads/2022/04/ICER-White-Paper_The-Next-Generation-of-Rare-Disease-Drug-Policy_040722.pdf. 97. Pearson, C., Schapiro, L. & Pearson, S. (2022). The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability. Institute for Clinical and Economic Review. https://icer.org/wp-content/uploads/2022/04/ ICER-White-Paper_The-Next-Generation-of-Rare-Disease-Drug-Policy_040722.pdf. 98. Lucas, F. & Tomassi, M. (2024). Optimizing Pricing And Access For Rare Disease Drugs. Oliver Wyman. https://www. oliverwyman.com/our-expertise/perspectives/health/2024/april/optimizing-pricing-and-access-for-rare-disease-drugs.html. 99. Rana, Proteesh and Chawla, Shalini. (2018). Orphan drugs: Trends and issues in drug development. Journal of Basic and Clinical Physiology and Pharmacology, 29(5), 10.1515/jbcpp-2017-0206. https://www.researchgate.net/ publication/324484571_Orphan_drugs_Trends_and_issues_in_drug_development. 100. The University of Arizona. (2024). Humanitarian Use Devices. https://research.arizona.edu/compliance/human-subjects- protection-program/collaborative-activities-banner-health/humanitarian-use. 101. Dooms, M. (2023). Orphan medical devices have come a long way. Orphanet Journal of Rare Diseases, PubMed Central, vol. 18. https://pmc.ncbi.nlm.nih.gov/articles/PMC10077604/. 102. Aartsma-Rus, A., Dooms, M., Le Cam, Y., OD Expert Group & Copenhagen Economics. (2021). Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group). Frontiers in Pharmacology, PubMed Central, vol. 12. https://pmc.ncbi.nlm.nih.gov/articles/ PMC8717920/. 103. Pearson, C., Schapiro, L. & Pearson, Steven. (2022). The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability. Institute for Clinical and Economic Review (ICER). https://icer.org/wp-content/ uploads/2022/04/ICER-White-Paper_The-Next-Generation-of-Rare-Disease-Drug-Policy_040722.pdf. 104. European Commission. (2024). Data protection in the EU. https://commission.europa.eu/law/law-topic/data-protection/ data-protection-eu_en. 105. Centers for Disease Control and Prevention (CDC). (2024). Health Insurance Portability and Accountability Act of 1996 (HIPAA). https://www.cdc.gov/phlp/php/resources/health-insurance-portability-and-accountability-act-of-1996-hipaa.html. 106. Deloitte. (2020). The China Personal Information Protection Law (PIPL). https://www2.deloitte.com/cn/en/pages/risk/ articles/personal-information-protection-law.html. 107. World Meteorological Organization (WMO). (2024). Climate and health data must be integrated. https://wmo.int/media/ news/climate-and-health-data-must-be-integrated. 108. von Hammerstein, C., Ahlawat, H., Craven, M., Wilson, M., Walker, O., Coghlan, B., Arora, D., Galvão, G.L., Moreira, M.S., Barreto, M., Vieira, P .G., van der Horst, K. & Ergüín, P .N. (2024). Health-related climate adaptation: How to innovate and scale global action for local needs. McKinsey Health Institute. https://www.mckinsey.com/mhi/our-insights/health- related-climate-adaptation-how-to-innovate-and-scale-global-action-for-local-needs. 109. Desai, A.N., Kraemer, M.U.G., Bhatia, S., Cori, A., Nouvellet, P ., Herringer, M., Cohn, E.L., Carrion, M., Brownstein, J.S., Madoff, L.C. & Lassmann, B. (2019). Real-time Epidemic Forecasting: Challenges and Opportunities. Health Security, PubMed Central, vol. 17, no. 4. https://pmc.ncbi.nlm.nih.gov/articles/PMC6708259/. 110. Global Virome Project. (2021). A collaborative scientific initiative to discover zoonotic viral threats & stop future pandemics. https://www.globalviromeproject.org/. 111. World Meteorological Organization (WMO). (2024). Climate and health data must be integrated. https://wmo.int/media/ news/climate-and-health-data-must-be-integrated. 112. Burjeel Holdings. (2024). Burjeel Holdings Launches New Initiative Focusing on Climate-Related Health Impacts . https://burjeelholdings.com/news-and-media/burjeel-holdings-launches-new-initiative-focusing-on-climate-related-health- impacts/. 113. Roy, E.D., Morzillo, A.T., Seijo, F., Reddy, S.M.W., Rhemtulla, J.M., Milder, J.C., Kuemmerle, T. & Martin, S.L. (2013). The Elusive Pursuit of Interdisciplinarity at the Human—Environment Interface. BioScience, vol. 63, no. 9, pp. 745-753. https://academic.oup.com/bioscience/article/63/9/745/260778. 114. Centers for Disease Control and Prevention (CDC). (2019). Climate and health: a guide for cross-sector collaboration. https://stacks.cdc.gov/view/cdc/82203. 115. Sources: –Fresenius. (2022). Climate target set: Fresenius to be climate neutral by 2040. https://www.fresenius.com/node/6322. –Roche. (2024). Minimise the environmental footprint. https://www.roche.com/about/sustainability/fighting-climate- change. –Novo Nordisk. (2024). Zero environmental impact. https://www.novonordisk.com/sustainable-business/zero- environmental-impact.html. Healthcare in a Changing Climate: Investing in Resilient Solutions 45